Holen Sie sich die Stockscreener-App
7.46
0.00%
0.00
Handel nachbörslich:
7.46
Kamada Ltd Aktie (KMDA) Neueste Nachrichten
Goalscorer Kamada credits ex-Palace boss Glasner for his Japan turnaround - The Japan Times
Daichi Kamada steals a point - The Financial Express
Crystal Palace at World Cup: Daichi Kamada reacts to ‘lucky’ equaliser vs Netherlands - Read Crystal Palace
How Kamada became Japan’s unlikely hero in World Cup classic vs Netherlands - The Indian Express
Japan vs Netherlands FIFA World Cup Match Result: Kamada's 88th-minute heroics rescue Japan in dramatic d - The Times of India
Daichi Kamada’s Late Header Gives Japan a 2-2 Draw with the Netherlands in World Cup Opener for Both - Kiripost
World Cup 2026: Kamada’s late header snatches draw for Japan against Netherlands - Business News Nigeria
Netherlands vs Japan highlights: Daichi Kamada’s late equalizer rescues Samurai Blue in FIFA World Cup th - The Times of India
Japan vs Netherlands: Kamada's Late Goal Secures 2-2 Draw - The News Mill
Kamada’s Late Header Earns Japan Thrilling 2-2 Draw Against Netherlands - NewsGhana
FIFA World Cup 2026: Late Kamada goal gives Japan point against NetherlandsNED vs JAP player ratings - Sportstar
KMDA Q1 2026 Earnings: EPS Misses Estimates Amid Operational ChallengesNext Quarter Guidance - newsline.com
KMDA Q1 2026 Earnings: EPS Misses Estimates Amid Revenue Disclosure GapRevenue Surprise History - newsline.com
Kamada (KMDA) Q1 2026 Earnings: EPS Misses Estimates, Stock DeclinesGuidance Accuracy Score - newsline.com
Why Is Kamada Ltd. (KMDA) Stock Down Today? - Meyka
KMDA Q1 2026 Earnings: EPS Misses Estimates as Stock Slips -2.85%Forward Guidance Trends - newsline.com
KMDA News | KAMADA LTD (NASDAQ:KMDA) - ChartMill
Kamada: Undervalued, Yet Execution Risks Keep It A Hold (NASDAQ:KMDA) - Seeking Alpha
Kamada gets FDA approval for Rapid Fluorescent Focus Inhibition Test laboratory - TipRanks
Kamada (KMDA) Receives FDA Nod for New Fluorescent Focus Inhibition Test - GuruFocus
Kamada receives FDA approval for rabies antibody testing lab By Investing.com - Investing.com Australia
Kamada receives FDA approval for rabies antibody testing lab - Investing.com
Kamada Receives FDA Approval for In-House Rabies Virus Neutralization Testing Laboratory - geneonline.com
Kamada Wins FDA Nod for New In‑House Rabies Antibody Testing Lab - TipRanks
Kamada Announces FDA Approval of its New In-House Rabies Virus Neutralization Testing Laboratory - The Manila Times
Kamada (KMDA) wins FDA approval for in-house RFFIT rabies antibody testing lab - Stock Titan
Kamada (KMDA) Slides 0.64% as Price Tests Key Support Zone Near $7.42Sign of Weakness - The Legal Advocate
Kamada Ltd. (KMDA) Holds Steady Near Support as Trading Volume Remains ModerateRTH Profile - newsline.com
Kamada Ltd stock (IL0010952647): shares stabilize after recent results as investors eye valuation me - AD HOC NEWS
Kamada Ltd. (KMDA) Climbs 1.66% as Shares Approach Key Resistance at $8.36Jurik MA - The Legal Advocate
KMDA Q1 2026 Earnings: EPS Misses Estimates Despite Positive Stock ReactionOperating Margin Analysis - The Legal Advocate
Kamada Q1 earnings call highlights - MSN
KMDA Insider Transactions: Officers & Directors File Initial Holdings, May 21, 2026 - Meyka
Kamada Ltd Earnings Call Balances Growth And Risks - The Globe and Mail
Benchmark reiterates Kamada stock Buy rating after Q1 miss By Investing.com - Investing.com Australia
Benchmark reiterates Kamada stock Buy rating after Q1 miss - Investing.com
KMDA Kamada shares rise 351 on strong 121 revenue growth despite EPS missEvent Driven - Newser
Kamada Ltd stock (IL0010952647): biotech shares in focus after recent quarterly update - AD HOC NEWS
Kamada Ltd stock (IL0010952647): plasma?derived therapies under the spotlight after recent updates - AD HOC NEWS
H.C. Wainwright reiterates Kamada stock rating on guidance outlook - Investing.com UK
Kamada Ltd. (NASDAQ:KMDA) Q1 2026 Earnings Call Transcript - Insider Monkey
H.C. Wainwright reiterates Kamada stock rating on guidance outlook By Investing.com - Investing.com Australia
Kamada Ltd (KMDA) Q1 2026 Earnings Call Highlights: Strategic Gr - GuruFocus
Kamada Ltd.Ordinary Shares (NQ: KMDA - FinancialContent
Kamada Falls Short on Q1 2026: $0.07 EPS vs $0.12 Expected - AlphaStreet
Kamada reports Q1 EPS 7c, consensus 12c - TipRanks
2.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):